Two human monoclonal SARS-CoV-2 antibodies that maintain neutralizing potency against the SARS-CoV-2 Omicron BA.1 and BA.2 variants  

作　　者：Qianqian Zheng Liangwei Duan Zhihua Jiang Tingxuan Gu Bojie Zhang Jiaoyang Li Yang Zhang Shiyu Zhang Yinming Liang Hui Wang 

机构地区：[1]Henan Key Laboratory of Immunology and Targeted Drugs,School of Laboratory Medicine,Xinxiang Medical University,Xinxiang,Henan 453003,China [2]Henan Collaborative Innovation Center of Molecular Diagnosis and Laboratory Medicine,Xinxiang Medical University,Xinxiang,Henan 453003,China [3]KMD Bioscience(Tianjin)Company Limited,Tianjin 301723,China [4]Department of Pathophysiology,School of Basic Medical Sciences,Academy of Medical Science,College of Medicine,Zhengzhou University,Zhengzhou,Henan 450001,China [5]China-US(Henan)Hormel Cancer Institute,Zhengzhou,Henan 450008,China

出　　处：《Genes & Diseases》2023年第3期664-667,共4页基因与疾病（英文）

基　　金：supported by The National Natural Science Foundation of China(No.81871312);the Key Scientific and Technological Project of Henan Province(No.222102310025);The International Joint Research Laboratory for Recombinant Pharmaceutical Protein Expression System of Henan(KFKTYB202210);the 111 Project(No.D20036).

摘　　要：The pandemic caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)continues to sweep the globe with devastating consequences on human lives and world economy.As an RNA virus,SARS-CoV-2 has a relatively high mutation rate and is rapidly evolving.Thus,new SARS-CoV-2 variants continued to emerge,5 of which were designated by the World Health Organization(WHO)as variants of concern(VOCs),Alpha(B.1.1.7).

关 键 词：acute MONOCLONAL respiratory 

分 类 号：R563.1[医药卫生—呼吸系统]